Total serum cholesterol levels and Alzheimer's dementia in patients with Down syndrome

International Journal of Geriatric Psychiatry

Volumn 23, Issue 9, 2008, Pages 937-942

  Prasher, V P ^a   Airuehia, E ^a   Patel, A ^c   Haque, M S ^b  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c Institute for Clean Growth and Future Mobility   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid; Apolipoprotein E; Cholesterol; Dementia; Down syndrome

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL;

ADOLESCENT; ADULT; ALZHEIMER DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DOWN SYNDROME; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PATHOGENESIS; PROTEIN BLOOD LEVEL;

ADOLESCENT; ADULT; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; CHOLESTEROL; DEMENTIA; DOWN SYNDROME; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; YOUNG ADULT;

EID: 52649124349     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2014     Document Type: Article

References (27)

1. Aylward EH, Burt DB, Thorpe LU, et al. 1997. Diagnosis of dementia in individuals with intellectual disability. Journal of Intellectual Disability Research 41: 152-164.
2. Boerwinkle E, Sing CF. 1987. The use of measured genotype information in the analysis of quantitative phenotypes in man. III. Simultaneous estimation of the frequencies and effects of the apolipoprotein E polymorphism and residual polygenic wffects on cholesterol, betalipoprotein and triglyceride levels. Ann Hum Genet 51(3): 211-226.
3. Bonarek M, Barberger-Gateau P, Letenneur L, et al. 2000. Relationships between Cholesterol, apolipoprotein E, polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiol 19: 141-148.
4. Evans RM, Emsley CL, Gao S, et al. 2000. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 54: 240-242.
5. Farrer LA, Cupples LA, Haines JL, et al. 1997. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A mets-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278(16): 1349-1356.
6. Jarvik GP, Wijsman EM, KuKull WA, et al. 1995. Interaction of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45: 1092-1096.
7. Kivipelto M, Helkala E, Laakso M, et al. 2001. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322: 1447-1451.
8. Koch W, Ehrenhaft A, Griesser K, et al. 2002.TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. Clin Chem Lab Med 40: 1123-1131.
9. Kuo YM, Emmerling MR, Bisgaier CL, et al. 1998. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abets 1-42. levels. Biochem Biophys Res Commun 252: 711-715.
10. Launer LJ, White LR, Petrovitch H, et al. 2001. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 57: 1447-1452.
11. Li G, Shofer JB, Kukull WA, et al. 2005. Serum cholesterol and risk of Alzheimer's disease. Neurology 65: 1045-1050.
12. Mann DMA. 1988. The pathological association between Down Syndrome and Alzheimer disease. Mechanisms Ageing Develop 43: 99-136.
13. Mayeux R, Saunders AM, Shea S, et al. 1998. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's diease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Eng J Med 338(8): 506-511.
14. Mielke MM, Zandi PP, Sjogren M, et al. 2005. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 64(10): 1689-1695.
15. Miller LJ, Chacko R. 2004. The role of cholesterol and statins in Alzheimer's disease. Ann-Pharmacotherapy 38(1): 91-98.
16. Notkola IL, Sulkava R, Pekkanen J, et al. 1998. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17: 14-20.
17. Oliver C, Holland AJ. 1986. Down's syndrome and Alzheimer's disease: a review. Psychological Medicine 16: 307-322.
18. Prasher VP. 1995. Age-specific prevalence, thyroid dysfunction and depressive symptomatology in adults with Down syndrome and dementia. International Journal of Geriatric Psychiatry 10: 25-31.
19. Prasher VP. 2005. Alzheimer's Disease, Dementia, Down syndrome and Intellectual Disabilities. Radcliffe Press: Oxford, UK.
20. Prasher VP, Adams C, Holder R. 2003. Long term safety and efficacy of Donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome. Open label study. Int J Geriatr Psychiatry 18: 549-551.
21. Sparks DL, Sabbagh D, Connor H, et al. 2006. Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl 185: 78-86.
22. Tan ZS, Seshadri S, Beiser A, et al. 2003. Plasma total cholesterol level as a risk factor for Alzheimer disease. The Framingham study. Arch Intern Med 163: 1053-1057.
23. World Health Organisation. 1993. The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research, WHO: Geneva.
24. Wisniewski KE, Wisniewski HM, Wen GY. 1985. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurology 17: 278-282.
25. Wood WG, Igbavboa U, Eckert GP, et al. 2005. Is hypercholesterolemia a risk factor for Alzheimer's disease? Mol Neurobiol 31(1-3): 185-192.
26. Zhou B, Teramukai S, Fukushima M. 2007. Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. Dement Geriatr Cogn Disord 23(3): 194-201.
27. Zigman WB, Schupf N, Jenkins EC, et al. 2007. Cholesterol level, statin use and Alzheimer's disease in adults with Down syndrome. Neurosci Lett 416(3): 279-284.